Renova’s Gene Therapy To Reverse Heart Remodeling In CHF
This article was originally published in The Pink Sheet Daily
Executive Summary
Reversing the “remodeling” of the heart in congestive heart failure with an investigational gene therapy is one of the aims of the San Diego-based biotech that is planning late-stage clinical development.
You may also be interested in...
Gene Therapy: Cures Within Reach
After rocky beginnings, there is increasing optimism about the potential for gene therapy to make an impact in rare disease. Promising data from late-stage clinical trials, improved safety, and the first Western regulatory approval of a gene therapy are now driving numerous initial public offerings, venture capital financings, and tie-ups with major pharmaceutical companies.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.